Venture Capital and how to find, approach and work with VC firms

The following company is one of the companies presenting at the 22nd Annual Investors Choice Venture Capital Conference:

Prolexys – Drug Discovery  Salt Lake City, UT
 
Prolexys Pharmaceuticals, Inc. is focused on discovering small molecule drugs that act at novel therapeutic targets. The Company’s therapeutic focus is on cancer and cardiovascular indications where Prolexys has identified novel, druggable therapeutic targets. Small molecules that act at these targets have been identified and tested in cell and animal models of disease. Lead programs include a) PRLX82845, a compound with selective anti-tumor activity, b) PRLX8025, a compound for colon cancer, c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.